Progyny (NASDAQ:PGNY) EVP Sells $29,998.98 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 1,199 shares of Progyny stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total value of $29,998.98. Following the sale, the executive vice president owned 83,316 shares in the company, valued at $2,084,566.32. This trade represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Allison Swartz also recently made the following trade(s):

• On Thursday, June 4th, Allison Swartz sold 599 shares of Progyny stock. The stock was sold at an average price of $25.08, for a total value of $15,022.92.

Progyny Price Performance

Shares of PGNY opened at $25.86 on Monday. The firm has a market cap of $2.03 billion, a PE ratio of 33.58, a PEG ratio of 2.28 and a beta of 1.03. The stock’s fifty day moving average price is $20.58 and its two-hundred day moving average price is $22.26. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s revenue was down 26.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts anticipate that Progyny, Inc. will post 1.07 earnings per share for the current fiscal year.

Progyny announced that its Board of Directors has initiated a stock buyback plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several analysts have issued reports on PGNY shares. Citigroup restated an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. KeyCorp lowered their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. Truist Financial boosted their target price on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Jefferies Financial Group restated a “buy” rating and issued a $30.00 target price on shares of Progyny in a research note on Friday, March 6th. Finally, BTIG Research lowered their target price on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Progyny presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.67.

Hedge Funds Weigh In On Progyny

Hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. grew its position in shares of Progyny by 57.1% in the third quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after purchasing an additional 256,078 shares in the last quarter. Intech Investment Management LLC grew its position in shares of Progyny by 336.0% in the third quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock valued at $3,655,000 after purchasing an additional 130,885 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares in the last quarter. Algert Global LLC grew its position in shares of Progyny by 35.1% in the third quarter. Algert Global LLC now owns 595,805 shares of the company’s stock valued at $12,822,000 after purchasing an additional 154,930 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Progyny by 79.2% in the third quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares in the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.